about
Lipoxin A4 stimulates calcium-activated chloride currents and increases airway surface liquid height in normal and cystic fibrosis airway epithelia.miR-31 dysregulation in cystic fibrosis airways contributes to increased pulmonary cathepsin S production.Physiological levels of lipoxin A4 inhibit ENaC and restore airway surface liquid height in cystic fibrosis bronchial epitheliumThe microbial community of the cystic fibrosis airway is disrupted in early life.Physiological impact of abnormal lipoxin A₄ production on cystic fibrosis airway epithelium and therapeutic potential.A functional variant of elafin with improved anti-inflammatory activity for pulmonary inflammation.The Role of Short-Chain Fatty Acids, Produced by Anaerobic Bacteria, in the Cystic Fibrosis AirwayDecreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation.The QT interval and psychotropic medications in children: recommendations for clinicians.Elafin, an elastase-specific inhibitor, is cleaved by its cognate enzyme neutrophil elastase in sputum from individuals with cystic fibrosisManaging end stage lung disease in children.Knowledge of statistical methods and their implications for clinical practice: a survey of paediatricians.Lipoxin A4 prevents tight junction disruption and delays the colonization of cystic fibrosis bronchial epithelial cells by Pseudomonas aeruginosa.miR-17 overexpression in cystic fibrosis airway epithelial cells decreases interleukin-8 production.Activation of P2RY11 and ATP release by lipoxin A4 restores the airway surface liquid layer and epithelial repair in cystic fibrosis.Lipoxin A₄-mediated KATP potassium channel activation results in cystic fibrosis airway epithelial repair.A secretory leukocyte protease inhibitor variant with improved activity against lung infection.Diagnosis and treatment of sleep related breathing disorders in children: 2007 to 2011.A role for whey acidic protein four-disulfide-core 12 (WFDC12) in the regulation of the inflammatory response in the lung.The findings of a clinical surveillance bronchoalveolar lavage programme in pre-school patients with cystic fibrosis.Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies.Adenotonsillectomy for obstructive sleep apnoea in children with Down Syndrome - No magic bullet.Pooling of bronchoalveolar lavage in children with cystic fibrosis does not adversely affect the microbiological yield or sensitivity in detecting pulmonary inflammation.Estimated population prevalence of obstructive sleep apnoea in a community of German third graders.Reduced 15-lipoxygenase 2 and lipoxin A4/leukotriene B4 ratio in children with cystic fibrosis.Resolvin D1 regulates epithelial ion transport and inflammation in cystic fibrosis airways.The benefit of taking a control sample when performing bronchoalveolar lavage.Infantile pulmonary capillary haemangiomatosis: a lethal form of pulmonary hypertension.LL-37 Complexation with Glycosaminoglycans in Cystic Fibrosis Lungs Inhibits Antimicrobial Activity, Which Can Be Restored by Hypertonic SalinePulmonary aspiration in preschool children with cystic fibrosisHigh concentrations of pepsin in bronchoalveolar lavage fluid from children with cystic fibrosis are associated with high interleukin-8 concentrationsVitamin D receptor agonists inhibit pro-inflammatory cytokine production from the respiratory epithelium in cystic fibrosisBronchoalveolar lavage-directed therapy in children with cystic fibrosis and Pseudomonas aeruginosa infectionMedicine: who needs it?Use of intrapulmonary percussive ventilation (IPV) in the management of pulmonary complications of an infant with osteogenesis imperfectaUse of post-exercise laryngoscopy to evaluate exercise induced dyspneaHemoptysis from bronchial varices associated with pulmonary vein stenosis: role of surgical repairActive video games as an exercise tool for children with cystic fibrosisSuccessful use of acetazolamide for central apnea in a child with Pitt-Hopkins syndromeAnaerobic bacteria cultured from cystic fibrosis airways correlate to milder disease: a multisite study
P50
Q34291214-20CD9439-0B1A-4F23-A9E4-0E56AFD95DFCQ34480433-001D9A13-6932-4848-B617-6B9EA102881CQ34582407-803A96E8-F21C-479A-A86B-1215541461ABQ34744222-871C1289-3825-481E-BBD6-661A1758A5BCQ35250351-71187DAF-6920-49EA-9DE8-8729CCB214EEQ35591399-4D0EA7F3-0AE5-44C4-84A5-8B9DF4CEA4C5Q35743588-F69D12C3-75BD-40B0-9D14-177636FC65B8Q36114167-8D265191-A116-41EF-B246-19BFF05F1A91Q36582252-DC046058-4816-4500-8500-97B62056F9A0Q36973716-866255BC-3EED-484A-BA82-9AA2C18A4E33Q38129179-35B7DE14-6FF6-46E4-A3AA-7D01FF2BE24EQ38439150-149AAEAB-CDA6-42F5-9233-48169964DB3EQ38777684-DBC5CAA0-4274-42C5-A980-512E87FE96A0Q38854640-15F6CBBC-8FB1-42EC-B598-603C4897154DQ39019151-2810D0DC-5867-41D6-AD6F-7582C0083CC6Q39149829-CB0948F7-E10D-4C17-86D5-5CF839640B61Q40996531-7B22311B-D04E-4BDD-B255-1218B81BAEF1Q41069730-D078C95E-F904-4426-919C-3D9C5FBFCF41Q41431968-55A367A8-4C09-4D21-BA60-30234F5BA4C2Q41656483-50A544D1-B453-456C-8F30-10B5158819CBQ43791316-E2B7D5FC-19EC-412F-A46F-AB4400D48F2DQ47660471-BE72CB30-E9F8-46E8-BCEB-E44194CC9C49Q47705430-0E88FEEC-22DD-40F0-9D97-34501EB3EC00Q48309676-5AAAFF83-5B67-4C49-AFC6-235B3733006AQ48320676-CAD81A78-C101-404F-BF9B-385033BC46F5Q49887932-1834D7B9-7E02-44A9-8A4C-9220C379A4F3Q51621082-0C84647A-E8C9-4A93-A10D-CB681943D101Q53426536-A0E0D159-38D5-44AD-818C-CAC0A25ADD2EQ58817684-32E5B960-812B-4DC9-AAB4-4740CAE8C8C3Q60044559-DEB9F8ED-046B-4B50-B16E-06530F5E214CQ60056981-59A0CD0B-8876-43F9-B0E1-AF77AE933CBDQ60056983-492B98E0-1370-4173-B0D5-2AE4931437F4Q82210618-FC81E64E-23B3-4B53-829C-3781C3152083Q83589336-3056E9F4-1FDB-47AE-A68B-282D266F1224Q84708479-E90565FF-3951-4587-9998-2E6068A0527EQ84757725-D09B4145-DD99-45B5-BC10-5CABB737CD1CQ85009401-FBA13BE5-1D07-4FA4-84F7-6C4C99D20010Q86643229-81DFA9E3-BC85-40F4-827C-DA4A41D25D19Q87164947-103DA5E6-87F1-4D79-B2F6-F610D925A1D4Q89266835-3FA82FC2-A069-4248-9286-25D036E4E574
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Paul McNally
@ast
Paul McNally
@en
Paul McNally
@es
Paul McNally
@nl
Paul McNally
@sl
type
label
Paul McNally
@ast
Paul McNally
@en
Paul McNally
@es
Paul McNally
@nl
Paul McNally
@sl
prefLabel
Paul McNally
@ast
Paul McNally
@en
Paul McNally
@es
Paul McNally
@nl
Paul McNally
@sl
P1053
I-3151-2013
P106
P21
P31
P3829
P496
0000-0001-7102-1712